David Kamelhar is a Respiratory physician affiliated with New York University. OpenAlex indexes 23 publications with 210 citations (h-index 3); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
404 Park Ave S
Suite 701
New York, NY 100168404
Telephone
212-685-6611Registry record last updated 18 Nov 2008.
Clinical trials
- Evaluation Of The Lung Microbiome In NTM Bronchiectasis
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insmed, Inc.Program year202515 payments
- GlaxoSmithKline, LLC.Program year202522 payments
- Philips North America LLCProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
45.9%Corticosteroid23.3%Trelegy Ellipta27%Arnuity Ellipta14%Qvar Redihaler14%Breztri Aerosphere12%Symbicort9%Fluticasone Propionate7%Budesonide-Formoterol Fumarate6%Dulera6%Breo Ellipta6%Part D<11 patientsbeta2-Adrenergic Agonist12.9%Albuterol Sulfate Hfa100%Part D≥149 patients+ 3 more classes in this area
Anti-infectives
34.4%Macrolide Antimicrobial8.9%Azithromycin100%Part D≥62 patientsAntimycobacterial6.8%Ethambutol Hcl100%Part D≥25 patients+ 7 more classes in this area
Metabolism & gastrointestinal
15.1%H2 blocker6%Famotidine100%Part D≥59 patientsCorticosteroid5.8%Prednisone100%Part D≥47 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lower airway dysbiosis in nontuberculous mycobacteria–positive bronchiectasis is associated with neutrophil extracellular trap–predominant severe phenotypes
American Journal of Respiratory and Critical Care Medicine
2026 - Lower Airway Dysbiosis Predict Disease Phenotype in NTM-Lung Disease
American Journal of Respiratory and Critical Care Medicine
2025 - Lower Airway Dysbiosis in Nontuberculous Mycobacterial Lung Disease Drives a Neutrophil Extracellular Trap-endotype and Lung Injury
American Journal of Respiratory and Critical Care Medicine
2025 - Distinct Air Pollutant Exposures in Patients With Bronchiectasis Are Associated With Differences in Airway Microbiome
American Journal of Respiratory and Critical Care Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Galetta, MD
New York University
Herbert Lepor, MD
New York University
Aasma Shaukat, MD
New York University
Jerry Shapiro, MD
New York University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”